-
A human health trajectory tracking framework using transfer learning based on gut microbial community data
Time of Update: 2023-02-01
In January 2023, the team of Professor Ning Kang of the Department of Systems Biology and Bioinformatics, School of Life Sciences, Huazhong University of Science and Technology, published a report entitled "Tracing human life trajectory using gut microbial communities by context-aware" in the internationally authoritative academic journal Briefings in Bioinformatics Deep Learning" proposes a human health trajectory tracking framework based on intestinal microbial community data using transfer learning, which initially solves the problem of age-dependent human health status diagnosis.
-
【Probe 24H】Customized penis transplantation in the UK! The world's first new drug to delay the process of type 1 diabetes has been approved
Time of Update: 2023-01-04
Introduction: Customized penis transplantation is implemented in the UK; The world's first new drug to delay the onset of type 1 diabetes was approved; Rongcan Biotech completed tens of millions of yuan pre-A round financing.
-
Innovent and UNION Therapeutics announced the completion of the first patient dosing of a novel PDE4 inhibitor, Orismilast (IBI353), in a Phase I clinical trial in China
Time of Update: 2023-01-01
ROCKVILLE, USA, Suzhou, China, and HEILEUP, Denmark, Dec. 5, 2022The study (CTR 20222393) is a Phase I dose-escalation clinical study with multiple doses in healthy subjects, the main objective of which is to evaluate the pharmacokinetic (PK) characteristics, safety and tolerability of Chinese healthy subjects after receiving multiple doses of orismilast, in order to support the subsequent clinical development of orismilast in multiple indications such as psoriasis and atopic dermatitis (AD).
-
The clinical trial application of the long-term biological pan-FGFR kinase inhibitor KIN-3248 was approved
Time of Update: 2022-12-30
js?cdnversion='+~(-new Date()/36e5)];Recently, Jingjiu Biologics announced that the clinical trial application of KIN-3248, a new generation of FGFR inhibitor, has obtained the implied license of the Center for Drug Review (CDE) of the National Medical Products Administration, and intends to carry out clinical research in Chinese mainland.
-
Professor Jiang Shujuan: Under the normalization of the new crown epidemic, long-acting neutralizing antibodies are expected to provide additional protection for people with low immunity
Time of Update: 2022-10-03
A drug that can be used for COVID-19 prevention. The COVID-19 pandemic has lasted for nearly three years and has had a huge impact on human life, health and daily life. In China, with the large-scale
-
Guangxi Food and Drug Administration: Three months! The special rectification of online drug sales is coming
Time of Update: 2022-09-21
Recently, the Guangxi Food and Drug Administration issued a notice to carry out a three-month special action for the supervision of the drug network market in the whole region, focusing on rectifying
-
Decoction pieces of traditional Chinese medicine are frequently "named", and digital transformation and upgrading need to be accelerated
Time of Update: 2022-08-30
For example, on August 17, the Anhui Provincial Food and Drug Administration issued an announcement saying that 7 companies of traditional Chinese medicine decoction pieces (including formula granules) had project defects, of which 5 companies rectified within a time limit, and 2 companies suspended production, warned and interviewed .
-
Competition is fierce
Time of Update: 2022-08-15
com, in 2021, the total sales of isosorbide mononitrate sustained-release tablets in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 1 billion yuan According to data from Minet.
-
The evaluation of basic medicines in tertiary hospitals has changed
Time of Update: 2022-05-25
When the 2018 version of the tertiary hospital index assessment was issued, the "1+X" and "9-8-6" basic drug allocation requirements for basic drugs had not yet been introduced (it was only introduced in the document on shortage drug management in 2019), At that time, items (18) and (19) did not have extended indicators for the assessment of the number of varieties.
-
First imitation
Time of Update: 2022-05-21
During the whole process of preoperative anesthesia, intraoperative sleep, and postoperative awakening, three types of drugs, such as sedatives, analgesics, and muscle relaxants, are usually required to act synergistically, and to reverse the patient's functional state in a timely manner .
-
EGFR 20ins mutant lung cancer, Amivantamab is better than the existing treatment
Time of Update: 2022-04-27
Amivantamab compared with real-world therapies in patients with advanced non- small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
-
Two local pharmaceutical companies, pharmaceutical business revenue in 2021 exceeds 20 billion yuan
Time of Update: 2022-03-06
On the whole, most multinational pharmaceutical companies have achieved growth in performance driven by new drugs, and their revenue in China has basically remained above the baseline of 20 billion yuan .
-
The financing wave of pharmaceutical companies continues. Recently, many pharmaceutical companies announced the completion of financing of hundreds of millions of yuan
Time of Update: 2022-01-09
("Omini Pharmaceutical"), an innovative pharmaceutical company focusing on the development of respiratory drug delivery technology, also announced that it has completed the D round of financing of hundreds of millions of yuan.
-
Lose again
Time of Update: 2021-11-05
This study aims to evaluate the efficacy and safety of Merck's TGF-β/PD-L1 bifunctional fusion protein bintrafusp alfa combined with gemcitabine and cisplatin in the first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) .
-
Express "first-in-class" new target
Time of Update: 2021-10-01
▎The content team editor of WuXi AppTec today, Trigone Pharma announced that it has reached a strategic cooperation agreement with 4C Biomed to develop a new type of intravesical immunotherapy .
"Reference: [1] Trigone Pharma Announces a Strategic Collaboration with 4C Biomed to Develop a Novel Treatment for High-Grade Bladder Cancer.
